Diabetes

Servier a leader in diabetes

 

Servier with over 40 years of experience and more than 20 million treated patients around the world.  

We have been committed for many years to fighting diabetes, a complex and progressive disease that affects 463 million people worldwide.

Servier has always focused on the treatment of type 2 diabetes and its complications. To strengthen its involvement in diabetes complications, such as nonalcoholic steatohepatitis (NASH), Servier signed a partnership with a biotech company based on the West Coast of the United States in 2019.  

Not well known until recently, NASH is a chronic condition that results from fat accumulation in the liver.

 

 

 

Type 2 diabetes is a complex and progressive disease that affects 463 million people worldwide and that will affect 700 million people by 2045.

 

Diabetes is the 7th cause of death worldwide, with more than 4.2 million deaths last year. But also, Diabetes has a dramatic socioeconomic impact that caused at least USD 760 billion dollars in health expenditure in 2019 - 10% of total spending on adults. Nowadays 1 in 11 people of working age are living with diabetes, and among these, 79% of adults with diabetes are living in low and middle-income countries like the Central American and Caribbean countries.  

Diabetes, hypertension, or a combination of both, cause 80% of end-stage renal disease globally. Additionally, eye disease (diabetic retinopathy) is the leading cause of blindness worldwide.

 

All of this is why type 2 diabetes control proves to be a challenge for all the patients, doctors and health care systems. Servier has been committed to fight against this high-prevalence disease and has been focused on the management of the control of diabetes and its complications for more than 60 years.        

* Diamicron 80 mg first marketed in 1973. 2- Calculation based on primary sales in units (MAT sales May 2018 divided by 12 ), adjusted with average daily dose of 85 mg/day (source: IMS) and 62%* adherence to treatment.

**Khunti K et al Diabetes Care. 2017;40(11):1588-1596.

***. IDF Atlas. 9th edition , 2019. Diamicron MR is indicated in non-insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose.